This widespread variation in strategies may contribute to undesirable outcomes that are characterized by poor seizure control and added deficits.
Although 2 patients experienced an increase in seizure frequency, the remaining patients did not experience a change in frequency.
Countable seizure types were recorded in parents' and caregivers' clinical diaries during a 4-week baseline period.
The investigators sought to detect whether neuroimaging during an emergency department visit was associated with acute changes in the management of patients.
The risk for late-onset epilepsy was lower in patients with higher physical activity levels and moderate alcohol intake.
Recurrence of seizures was reported in 28.2% of patients who attempted withdrawal.
Clobazam is currently available as oral tablets and suspension under the trade name Onfi (Lundbeck).
Approximately 78% of treated patients experienced at least 1 treatment-related adverse event.
The findings offer some reassurance for clinicians and for pregnant women who are successfully treated with enzyme-inducing ACDs.
Diacomit was evaluated in 2 multicenter, placebo-controlled, double-blind, randomized studies.
The results of this review are applicable primarily to persons with focal onset seizures, with 88% of included participants experiencing this type of seizure at baseline.
Investigators assessed demographic and epilepsy-specific factors independently associated with anxiety, including lesions and seizure focus localization.
An expert subcommittee was formed consisting of members of the AAN and AES to update the 2004 evidence-based guidelines on epilepsy treatment with AEDs.
The NDA for IM/IV Captisol-Enabled Fosphenytoin has been accepted for review and given a Prescription Drug Fee User Act date, by the FDA.
Potentially modifiable risk factors in midlife are associated with the risk of developing late-onset epilepsy.
Claims data spanning 4 years were obtained from a pediatric accountable care organization.
The safety and efficacy of clobazam monotherapy in patients with new-onset focal or generalized seizures was investigated in a new Cochrane systematic review.
The efficacy was reported to be significantly higher in patients who had taken benzodiazepines.
Causes of death in patients with epilepsy were assessed to determine the presence of cardiac pathology.
The FDA has approved an abbreviated New Drug Application for Vigadrone, the generic alternative to Sabril powder for oral solution.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction